关注
Livia Stanger
Livia Stanger
在 umich.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
DHA 12‐LOX‐derived oxylipins regulate platelet activation and thrombus formation through a PKA‐dependent signaling pathway
A Yamaguchi, L Stanger, CJ Freedman, M Standley, T Hoang, R Adili, ...
Journal of Thrombosis and Haemostasis 19 (3), 839-851, 2021
252021
Supplementation with omega‐3 or omega‐6 fatty acids attenuates platelet reactivity in postmenopausal women
A Yamaguchi, L Stanger, JC Freedman, A Prieur, R Thav, J Tena, ...
Clinical and Translational Science 15 (10), 2378-2391, 2022
62022
Bioactive lipid regulation of platelet function, hemostasis, and thrombosis
L Stanger, M Holinstat
Pharmacology & Therapeutics, 108420, 2023
52023
Antiplatelet strategies: past, present, and future
L Stanger, A Yamaguchi, M Holinstat
Journal of Thrombosis and Haemostasis 21 (12), 3317-3328, 2023
32023
The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor
L Stanger, A Yamaguchi, P Yalavarthi, S Lambert, D Gilmore, ...
Blood 142 (18), 1556-1569, 2023
32023
Experimental venous thrombus resolution is driven by IL-6 mediated monocyte actions
AT Obi, SB Sharma, MA Elfline, CE Luke, AR Dowling, Q Cai, AS Kimball, ...
Scientific Reports 13 (1), 3253, 2023
32023
Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice
R Adili, M Jackson, L Stanger, X Dai, M Li, BX Li, M Holinstat
Clinical and Applied Thrombosis/Hemostasis 27, 10760296211018510, 2021
22021
CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists
L Stanger, P Yalavarthi, S Lambert, A Rickenberg, K Goerger, D Gilmore, ...
Blood 142, 1188, 2023
2023
HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding
L Stanger, M Holinstat, S Lambert, P Yalavarthi, N Bergh, B Dahlof
Blood 142, 1195, 2023
2023
HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner
M Holinstat, L Stanger, S Lambert, B Dahlof, N Bergh
European Heart Journal 44 (Supplement_2), ehad655. 2857, 2023
2023
Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis
L Stanger, S Lambert, A Yamaguchi, P Yalavarthi, B Dahlof, N Bergh, ...
European Heart Journal 44 (Supplement_2), ehad655. 2856, 2023
2023
Investigating the catalytic efficiency of C22-Fatty acids with LOX human isozymes and the platelet response of the C22-oxylipin products
M Tran, L Stanger, S Narendra, M Holinstat, TR Holman
Archives of Biochemistry and Biophysics 747, 109742, 2023
2023
The Eicosanoid Analogue Cs585 Represents A First-in-class In Prevention Of Platelet Activation And Thrombosis Through Direct Activation Of The Prostacyclin Receptor
A Yamaguchi, S Lambert, L Stanger, P Yalavarthi, A Rickenberg, A White, ...
Arteriosclerosis, Thrombosis, and Vascular Biology 43 (Suppl_1), A122-A122, 2023
2023
系统目前无法执行此操作,请稍后再试。
文章 1–13